Pharsight

Vyndaqel patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8168663 FOLDRX PHARMS Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof
Dec, 2023

(2 months from now)

US7214695 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Apr, 2024

(6 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7214696 FOLDRX PHARMS Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding
Dec, 2023

(2 months from now)

US8653119 FOLDRX PHARMS Methods for treating transthyretin amyloid diseases
Jan, 2024

(3 months from now)

Vyndaqel is owned by Foldrx Pharms.

Vyndaqel contains Tafamidis Meglumine.

Vyndaqel has a total of 4 drug patents out of which 0 drug patents have expired.

Vyndaqel was authorised for market use on 03 May, 2019.

Vyndaqel is available in capsule;oral dosage forms.

Vyndaqel can be used as treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm).

Drug patent challenges can be filed against Vyndaqel from 2023-05-04.

The generics of Vyndaqel are possible to be released after 03 May, 2026.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity (NCE) May 3, 2024
Orphan Drug Exclusivity (ODE) May 3, 2026

Drugs and Companies using TAFAMIDIS MEGLUMINE ingredient

NCE-1 date: 2023-05-04

Market Authorisation Date: 03 May, 2019

Treatment: Treatment of the cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis (attr-cm)

Dosage: CAPSULE;ORAL

More Information on Dosage

VYNDAQEL family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic